Cell transfer regimens in patients with highly advanced surgically unresectable non-small cell lung cancer: significantly improved overall survival in patients with lower levels of serum immunosuppressive acidic protein.

Abstract

Sixty-one non-small cell lung cancer (NSCLC) patients with stage II and III/IV were enrolled and 49 completed immunotherapy. Patients were grouped based on immunosuppressive acidic protein (IAP). All patients received monthly intravenous infusions containing 1 x 10(10) (mean cell number per patient) ex vivo expanded and IFN-alpha-treated peripheral blood mononuclear cells. No patients had grade 2 or greater adverse events. The patients with < or = 580microg/ml of serum IAP levels (n=33) had significantly longer recurrence-free survival than those with > 580microg/ml of serum IAP levels (n=16). Patients with lower IAP levels are still under immunotherapeutic control after 27 months free of recurrence. The IAP levels may be a prognostic marker for treatment efficacy in NSCLC. This immunotherapeutic regimen was feasible and well tolerated in patients with advanced NSCLC in terms of prolongation of survival.

• Authors: Takusaburo Ebina, Yoshiaki Fujimiya
• Journal: Lung cancer (Amsterdam, Netherlands) (Lung Cancer) Vol. 60 Issue 2 Pg. 246-51 (May 2008) ISSN: 0169-5002 [Print] Ireland
• PMID: 17980454 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Biomarkers, Tumor
• Interferon-alpha
• Neoplasm Proteins
• immunosuppressive acidic protein

Topics

• Adult
• Aged
• Biomarkers, Tumor (blood)
• Carcinoma, Non-Small-Cell Lung (blood, mortality, therapy)
• Female
• Humans
• Immunotherapy, Adoptive (methods)
• Interferon-alpha (immunology, metabolism)
• Kaplan-Meier Estimate
• Killer Cells, Natural (immunology, transplantation)
• Lung Neoplasms (blood, mortality, therapy)
• Male
• Middle Aged
• Neoplasm Proteins (blood)
• Prognosis